Meanwhile, antibody blockades such as anti-PD-L1 and anti-PD-1 can bind to these secreted immune checkpoint molecules, leading to decreased antibody-based therapeutic outcomes.14 40 Patients with higher expression of soluble PD-L1 and PD-1 exhibited shorter overall survival rates and tumor-free survival than those with lower expression. Here, PDCD1 is linked to neoplasm.